Transforming the future
of hypertension care

Aktiia’s mission expands far beyond monitoring – to foster new opportunities in evaluation, treatment, and yielding never before possible insights.

Aktiia Healthcare Solution

Transforming the
future of hypertension care

Aktiia’s mission expands far beyond monitoring – to foster new opportunities in evaluation, treatment, and yielding never before possible insights.

Aktiia demonstrates
validated accuracy

Aktiia’s pivotal trial has proven Aktiia is as accurate as a cuff:2

  • In multiple body positions including sitting, lying and standing
  • Across Fitzpatrick skin tones 1-6
  • From low to high density follicle density
Read the Paper

CE Marked class IIa
medical device5

Systolic BP Accuracy:
0.45 ± 7.75 mmHg2

Diastolic BP Accuracy:
0.38 ± 6.86 mmHg2

Take a closer look at
Aktiia’s Healthcare Platform

Request a Demo

Based on over 20 years
of research 

Aktiia believes in complete transparency of our clinical trials. With over 100 peer-reviewed publications, Aktiia partners with global experts in the mission to transform hypertension.

Read a selection of our publications:

Aktiia 2021 / 01

Blood pressure from the optical Aktiia Bracelet: a 1-month validation study using an extended ISO81060-2 protocol adapted for a cuffless wrist device

Authors: Anna Vybornova, Erietta Polychronopoulou, Arlène Wurzner-Ghajarzadeh, Sibylle Fallet, Josep Sola and Gregoire Wuerzner

Read

Aktiia 2022 / 02

Guidance for the Interpretation of Continual Cuffless Blood Pressure Data for the Diagnosis and Management of Hypertension

Authors: Sola J, Cortes M, Perruchoud D, De Marco B, Lobo MD, Pellaton C, Wuerzner G, Fisher NDL and Shah J

Read

Aktiia 2021 / 03

Validation of the optical Aktiia bracelet in different body positions for the persistent monitoring of blood pressure

Authors: Josep Sola1, Anna Vybornova, Sibylle Fallet, Erietta Polychronopoulou, Arlene Wurzner‐Ghajarzadeh & Gregoire Wuerzner

Read

Aktiia 2022 / 04

Persistent use of Aktiia 24/7 Blood Pressure Monitor is Associated with Lower Blood Pressure in Hypertensive Patients

Authors: Josep Sola, David Perruchoud, Meritxell Cortes, Jay Pandit, Melvin D Lobo, Gregoire Wuerzner, Naomi D Fisher and Jay Shah

Read

Aktiia 2022 / 05

Monitoring the personalized effects of antihypertensive drugs using the Aktiia optical device: a 4-month follow up

Authors: Josep Sola, Fallet Sibyllea, Gregoire Wuerzner,

Read

Aktiia 2021 / 06

Towards the longitudinal measurement of day and night blood pressure with the Aktiia optical device

Authors: Josep Sola, Sibylle Fallet and David Perruchoud

Read

Aktiia 2021 / 01

Blood pressure from the optical Aktiia Bracelet: a 1-month validation study using an extended ISO81060-2 protocol adapted for a cuffless wrist device

Authors: Anna Vybornova, Erietta Polychronopoulou, Arlène Wurzner-Ghajarzadeh, Sibylle Fallet, Josep Sola and Gregoire Wuerzner

Read

Aktiia 2022 / 02

Guidance for the Interpretation of Continual Cuffless Blood Pressure Data for the Diagnosis and Management of Hypertension

Authors: Sola J, Cortes M, Perruchoud D, De Marco B, Lobo MD, Pellaton C, Wuerzner G, Fisher NDL and Shah J

Read

Aktiia 2021 / 03

Validation of the optical Aktiia bracelet in different body positions for the persistent monitoring of blood pressure

Authors: Josep Sola1, Anna Vybornova, Sibylle Fallet, Erietta Polychronopoulou, Arlene Wurzner‐Ghajarzadeh & Gregoire Wuerzner

Read

Aktiia 2022 / 04

Persistent use of Aktiia 24/7 Blood Pressure Monitor is Associated with Lower Blood Pressure in Hypertensive Patients

Authors: Josep Sola, David Perruchoud, Meritxell Cortes, Jay Pandit, Melvin D Lobo, Gregoire Wuerzner, Naomi D Fisher and Jay Shah

Read

Aktiia 2022 / 05

Monitoring the personalized effects of antihypertensive drugs using the Aktiia optical device: a 4-month follow up

Authors: Josep Sola, Fallet Sibyllea, Gregoire Wuerzner,

Read

Aktiia 2021 / 06

Towards the longitudinal measurement of day and night blood pressure with the Aktiia optical device

Authors: Josep Sola, Sibylle Fallet and David Perruchoud

Read

World’s largest BP dataset with 300 million data points1

Aktiia looks to the future of what our data offers

The first dynamic mapping of the blood pressure pattern

New insights that can transform hypertension care

Learn More

Aktiia looks to the future of what our data offers

The first dynamic mapping of the blood pressure pattern

New insights that can transform hypertension care

Learn More

Discover more how our hypertension specialists can help your project

contact us today

How to manage what is
not measured?

30% of adults suffer from hypertension8

46% of adults with hypertension​
are unaware that they have the condition8

75% of adults with hypertension do not measure their blood pressure weekly9

80% of those diagnosed do not have it under control.8

Resulting in the loss of 18 million lives each year as the leading cause of heart attack and stroke. At a cost of $370 billion per year, this is not sustainable.10

1 Aktiia Bracelet Clinical Motion Study. 2022.
2 Sola et al. Nature Scientific Reports. (2021) https://doi.org/10.1038/s41598-021-99294-w
3 After initial (2) months of use
4 Aktiia (2022) Product data. Unpublished.
5 Aktiia Bracelet G1 has been CE-marked under the Medical Device Regulation (EU)2017/745 as a class IIa medical device.
6 ISO81060-2 Criterion 1 requires the mean difference of test versus reference blood pressure measurements for both systolic and diastolic blood pressure to be less than 5 mmHg, with a standard deviation of less than 8 mmHg.
7 Aktiia (2022) Product data.
8 World Hypertension Day.” World Health Organization, https://www.who.int/news-room/fact-sheets/detail/hypertension. 23 Jan 2023.
9 Ostchega at al. Factors Associated with Home Blood Pressure Monitoring Among US Adults. American Journal of Hypertension. 2017
10 P Muntner et al. Trends in Blood Pressure Control Among US Adults With Hypertension, 1999-2000 to 2017-2018. JAMA. 2020;324(12):1190-1200.
11 American Heart Association, “2022 Heart Disease & Stroke Statistical Update Fact Sheet Global Burden of Disease”